GIM
CPRX

Glenmede Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Glenmede Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$13.4M Buy
680,224
+603,084
+782% +$12.4M 0.06% 274
2025
Q2 		$1.67M Buy
+77,140
New +$1.82M 0.01% 598

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Glenmede Investment Management's CPRX Position: Q3 2025 in Review

Glenmede Investment Management increased its Catalyst Pharmaceutical (CPRX) stake by 782% in Q3 2025, buying an estimated $12.4M and bringing the position to 680,224 shares worth $13.4M. The position accounts for 0.06% of the portfolio, ranked #274.

Glenmede Investment Management first reported a position in CPRX in Q2 2025 and has held it in 2 quarters since. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Glenmede Investment Management held 680,224 shares of Catalyst Pharmaceutical worth $13.4M as of Q3 2025.
  • Glenmede Investment Management bought 603,084 Catalyst Pharmaceutical shares in Q3 2025, an estimated $12.4M.
  • Catalyst Pharmaceutical made up 0.06% of Glenmede Investment Management's portfolio in Q3 2025, its #274 holding.
  • Glenmede Investment Management first reported a position in Catalyst Pharmaceutical in Q2 2025 and has held it in 2 quarters since.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.